McLaughlin P, Velasquez W S, Redman J R, Yung W K, Hagemeister F B, Rodriguez M A, Cabanillas F
Department of Hematology, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
J Natl Cancer Inst. 1988 Nov 2;80(17):1408-12. doi: 10.1093/jnci/80.17.1408.
Ten patients with parenchymal CNS lymphoma received combination chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin (DHAP), and additional therapy according to clinical circumstances. Two of four patients with primary CNS lymphoma achieved and remain in complete remission (CR). Four of six patients with CNS lymphoma at relapse also achieved CR. DHAP is active against CNS lymphoma. Further trials with DHAP, particularly in conjunction with other treatment modalities, are warranted.
10例实质性中枢神经系统淋巴瘤患者接受了地塞米松、大剂量阿糖胞苷和顺铂联合化疗（DHAP），并根据临床情况接受了额外治疗。4例原发性中枢神经系统淋巴瘤患者中有2例实现并维持完全缓解（CR）。6例复发中枢神经系统淋巴瘤患者中有4例也实现了CR。DHAP对中枢神经系统淋巴瘤有效。有必要对DHAP进行进一步试验，特别是与其他治疗方式联合使用时。
